Molecular mechanisms in cognitive frailty: potential therapeutic targets for oxygen-ozone treatment
- PMID: 31982474
- DOI: 10.1016/j.mad.2020.111210
Molecular mechanisms in cognitive frailty: potential therapeutic targets for oxygen-ozone treatment
Erratum in
-
Corrigendum to "Molecular mechanisms in cognitive frailty: Potential therapeutic targets for oxygen-ozone treatment" [Mech. Ageing Dev. 186 (2020) 111210].Mech Ageing Dev. 2022 Oct;207:111729. doi: 10.1016/j.mad.2022.111729. Epub 2022 Sep 2. Mech Ageing Dev. 2022. PMID: 36058726 No abstract available.
Abstract
In the last decade, cognitive frailty has gained great attention from the scientific community. It is characterized by high inflammation and oxidant state, endocrine and metabolic alterations, mitochondria dysfunctions and slowdown in regenerative processes and immune system, with a complex and multifactorial aetiology. Although several treatments are available, challenges regarding the efficacy and the costs persist. Here, we proposed an alternative non-pharmacological, non-side-effect, low cost therapy based on anti-inflammation, antioxidant, regenerative and anti-pathogens properties of ozone, through the activation of several molecular mechanisms (Nrf2-ARE, NF-κB, NFAT, AP-1, HIFα). We highlighted how these specific processes could be implicated in cognitive frailty to identify putative therapeutic targets for its treatment. The oxigen-ozone (O2-O3) therapy has never been tested for cognitive frailty. This work provides thus wide scientific background to build a consistent rationale for testing for the first time this therapy, that could modulate the immune, inflammatory, oxidant, metabolic, endocrine, microbiota and regenerative processes impaired in cognitive frailty. Although insights are needed, the O2-O3 therapy could represent a faster, easier, inexpensive monodomain intervention working in absence of side effects for cognitive frailty.
Keywords: Cognitive frailty; Gut microbiota; Inflammation; Oxidative stress; Oxygen-ozone therapy; Trace elements.
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare no conflict of interest.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical